Literature DB >> 3667593

Structure of the carbohydrate moiety of human interferon-beta secreted by a recombinant Chinese hamster ovary cell line.

H S Conradt1, H Egge, J Peter-Katalinic, W Reiser, T Siklosi, K Schaper.   

Abstract

The carbohydrate structure of the major oligosaccharide of human interferon-beta (IFN-beta) synthesized by a genetically engineered Chinese hamster ovary cell line has been determined. Analysis of the glycopeptidase F-released carbohydrates by sequential exoglycosidase treatment, methylation analysis, and fast atom bombardment-mass spectrometry revealed that 95% of the IFN-beta oligosaccharides had the following structure: (Formula: see text). The remaining 5% of the carbohydrates are probably tri- or higher antennary oligosaccharide chains. The major oligosaccharide of the recombinant IFN-beta is remarkably homogeneous with respect to terminal galactose sialylation. NeuAc, which is alpha 2-3-linked to galactose in the human IFN-beta secreted by Chinese hamster ovary cells, can be re-incorporated with an alpha 2-6 linkage in vitro, into enzymatically desialylated IFN-beta using rat liver Gal beta 1-4GlcNAc alpha 2-6 sialyltransferase. The sugar chain is important for maintaining protein solubility as shown by the fact that IFN-beta protein precipitates after deglycosylation with glycopeptidase F.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3667593

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Decreased affinity of recombinant antithrombin for heparin due to increased glycosylation.

Authors:  I Björk; K Ylinenjärvi; S T Olson; P Hermentin; H S Conradt; G Zettlmeissl
Journal:  Biochem J       Date:  1992-09-15       Impact factor: 3.857

2.  The crystal structure of human interferon beta at 2.2-A resolution.

Authors:  M Karpusas; M Nolte; C B Benton; W Meier; W N Lipscomb; S Goelz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

3.  Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

Authors:  L Runkel; W Meier; R B Pepinsky; M Karpusas; A Whitty; K Kimball; M Brickelmaier; C Muldowney; W Jones; S E Goelz
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

Review 4.  Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

5.  Identification of genes encoding N-glycan processing beta-N-acetylglucosaminidases in Trichoplusia ni and Bombyx mori: Implications for glycoengineering of baculovirus expression systems.

Authors:  Christoph Geisler; Donald L Jarvis
Journal:  Biotechnol Prog       Date:  2010 Jan-Feb

Review 6.  Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells.

Authors:  E Grabenhorst; P Schlenke; S Pohl; M Nimtz; H S Conradt
Journal:  Glycoconj J       Date:  1999-02       Impact factor: 2.916

Review 7.  Effects of glycosylation on the stability of protein pharmaceuticals.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

8.  Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon Beta-1a: potential implications for protein aggregation and immunogenicity.

Authors:  Riccardo Torosantucci; Victor S Sharov; Miranda van Beers; Vera Brinks; Christian Schöneich; Wim Jiskoot
Journal:  Mol Pharm       Date:  2013-05-02       Impact factor: 4.939

Review 9.  Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.

Authors:  Hans-P Hartung; Chris Polman; Antonio Bertolotto; Florian Deisenhammer; Gavin Giovannoni; Eva Havrdova; Bernhard Hemmer; Jan Hillert; Ludwig Kappos; Bernd Kieseier; Joep Killestein; Christophe Malcus; Manuel Comabella; Andrew Pachner; Huub Schellekens; Finn Sellebjerg; Krysztof Selmaj; Per Soelberg Sorensen
Journal:  J Neurol       Date:  2007-04-24       Impact factor: 4.849

Review 10.  Carbohydrate analysis throughout the development of a protein therapeutic.

Authors:  Elizabeth Higgins
Journal:  Glycoconj J       Date:  2009-11-04       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.